182 - Progress towards an EBV vaccine: Results of a Phase I, First-In-Human EBV gp350 Ferritin Nanoparticle Vaccine Candidate adjuvanted with Matrix-M®

Presenting Author(s)

• 

  Jessica Durkee-Shock, MD MHSc

  Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health
  Bethesda, Maryland, United States

Co-Author(s)

• HN

  Hanh Nguyen, BS

  Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health
  Bethesda, Maryland, United States
• AV

  Alexander C. Vostal, MD

  Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health
  Bethesda, Maryland, United States
• SH

  Sally Hunsberger, PhD

  Biostatistician/Mathematical statistician
  National Institute of Allergy and Infectious Diseases
  Bethesda, Maryland, United States
• MG

  Megan C. Grieco, MSPH

  National Institute of Allergy and Infectious Diseases
  Bethesda, Maryland, United States
• KG

  Krista Gangler, RN

  Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health
  Bethesda, Maryland, United States
• KB

  Karenna Barton, BS

  Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health
  Bethesda, Maryland, United States
• MP

  Maria Ploussiou, RN

  Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health
  Bethesda, Maryland, United States
• KL

  Kelly Liepshutz, PA

  Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc.
  Bethesda, Maryland, United States
• KM

  Kayla Morgan, RN

  Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health
  Bethesda, Maryland, United States
• AH

  Anna Hostal, BS

  Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health
  Bethesda, Maryland, United States
• MB

  Meghna Bagchi, BS

  Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health
  Bethesda, Maryland, United States
• LS

  Leonid Serebryannyy, PhD

  Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
  Bethesda, Maryland, United States
• MC

  Mike Castro, MS

  Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
  Bethesda, Maryland, United States
• MS

  Michael Sibilo, MS

  Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
  Bethesda, Maryland, United States
• MK

  Masaru Kanekiyo, PhD

  Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
  Bethesda, Maryland, United States
• LD

  Lesia Dropulic, MD

  Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health
  Bethesda, Maryland, United States
• KD

  Kennichi Dowdell, PhD

  Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health
  Bethesda, Maryland, United States
• WB

  Wei Bu, PhD

  Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health
  Bethesda, Maryland, United States
• JC

  Jeffrey I Cohen, MD

  Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health
  Bethesda, Maryland, United States